ABSTRACT
Introduction
Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma. Additional drugs include leukotriene-receptor antagonists, slow-release theophylline and the long-acting muscarinic antagonist (LAMA) tiotropium (approved in 2015). There is a need for more effective therapies, as many patients continue to have poorly controlled asthma.
Areas covered
New and developing long-acting non-adrenoreceptor synthetic drugs for the treatment of symptomatic chronic asthma despite treatment with an ICS alone or combined with a LABA.
Data was reviewed from studies published up until November 2016.
Expert opinion
Tiotropium improves lung function and has a modest effect in reducing exacerbations when added to ICS alone or ICS and LABA. The LAMAs umeclidinium and glycopyrronium are under development in fixed dose combination with ICS and LABA. Novel small molecule drugs, such as CRTH2 receptor antagonists, PDE4 inhibitors, protein kinase inhibitors and nonsteroidal glucocorticoid receptor agonists and 'off-label' use of licensed drugs, such as macrolides and statins are under investigation for asthma, although their effectiveness in clinical practice is not established. To better achieve the goal of developing effective novel small molecule drugs for asthma will require greater understanding of mechanisms of disease and the different phenotypes and endotypes of asthma.
INTRODUCTION
Asthma is a chronic inflammatory disease of the airways that affects over 300 million people worldwide, of whom 80% are adults and adolescents. The Global Initiative for Asthma (GINA) guideline for the pharmacological treatment of adults and adolescents with asthma recommends a step-wise approach to control symptoms and minimize future risk (Figure 1 Daily low dose inhaled corticosteroid (ICS) is the preferred treatment option for mild persistent asthma 1, 2 as ICS improves asthma control and lung function as well as reduces the risk of exacerbations and death 3, 4 . At step 3, the combination of low dose ICS and inhaled long-acting beta2-agonist (LABA) is recommended. The safety of LABAs for the treatment of asthma has been a major focus for discussion, although recent new research has provided reassurance that LABAs can be used safely in combination with ICS 5, 6 . Alternative less effective add-on options to a LABA are leukotriene-receptor antagonists and low dose theophylline 7 . At Step 4, the combination of a medium dose ICS and LABA plus as-needed short-acting beta2-agonist or low dose ICS and formoterol combination as maintenance and reliever treatment are recommended as first-line options. Add-on therapies for patients with uncontrolled asthma despite using the combination of a medium or high dose ICS and LABA are leukotriene-receptor antagonists and sustained-release theophylline, although evidence for their efficacy is based on clinical trials in patients receiving ICS alone and not when combined with a LABA. The longacting muscarinic antagonist (LAMA) tiotropium was included in the 2015 GINA guideline as an alternative add-on therapy for people with a history of exacerbations. After assessment by a specialist, add-on therapies at step 5 include tiotropium, monoclonal antibodies mepolizumab and omalizumab and low dose oral corticosteroid. The 2016 British Guideline on the management of asthma recommendations on pharmacological treatment are broadly similar to those advocated in the GINA guideline, although the British guideline no longer refers to numerical steps of treatment and uses descriptive terms only for each step 8 .
Despite the use of current therapies, surveys indicate that many patients have poorly controlled symptoms and experience frequent exacerbations 9, 10 . Poor asthma control can be due to factors other than uncontrolled disease, such as poor inhaler technique, non-adherence to drug treatment and co-morbidities, and these issues should be identified and managed before adding further treatment. For some individuals, particularly those with severe disease, there is an unmet need for improved therapies. This reviews summarizes the efficacy and safety of new long-acting non-adrenoreceptor synthetic drugs currently used in the clinic or that are under clinical development for patients with poorly controlled chronic asthma despite treatment with ICS alone or combined with a LABA (Table 1) . Evidence is obtained from key clinical therapeutic phase III trials, selected phase II trials and studies in 'real-life' populations that were published predominately in the last five years. 15 . Tiotropium produced improvements in the primary end-point, peak FEV1 at 24 weeks (174 ml 95% CI, 76-272 ml) compared with placebo, whereas asthma control questionnaire (ACQ) and asthma quality of life questionnaire (AQLQ) scores were not significantly improved with tiotropium. A 12-week phase III trial assessed the efficacy and safety of once-daily tiotropium 5 μg added to ICS plus one or more controller therapies in 392 adolescents with severe symptomatic asthma 16 and found no significantly improvement in peak FEV1 or ACQ score compared with placebo 16 .
LONG-ACTING MUSCARINIC ANTAGONISTS

Tiotropium add-on compared with doubling the dose of ICS
A Cochrane systematic review (1 trials, 210 participants) evaluated the efficacy and safety of adding a LAMA to any dose of an ICS compared with increasing the dose of ICS in adults whose asthma was not well controlled 17 . The review included one cross-over trial of 14 weeks duration 18 . The addition of tiotropium 18 μg once daily (dry powder suspension) compared to doubling low to medium dose of ICS resulted in a significant improvement in the primary outcome, morning peak expiratory flow (PEF) and non-significant reduction in a secondary outcome, severe exacerbations (OR 0.57, 95% CI 0.22 to 1.43). The addition of tiotropium resulted in an increase in FEV1 (100 ml) and slight decrease in ACQ score. . Overall, the authors of the systematic review concluded it was not possible to know whether adding tiotropium to ICS is more effective or safer than increasing the dose of ICS 17 . 
Tiotropium add-on compared with LABA
Tiotropium in real-life populations
A retrospective study of 2042 adults with asthma recorded in a United Kingdom primary care practice database that were prescribed tiotropium found that in the year after the addition of tiotropium compared with the previous year there was a decrease in the percentage of patients having at least one exacerbation, defined as an asthma-related hospital emergency department attendance or inpatient admission, or acute oral corticosteroid course (37% to 27%, p=0.001) and a reduction in the percentage having at least one acute respiratory event, defined as an exacerbation or antibiotic prescription with a lower respiratory consultation (58% to 47%, p=0.001) 24 . Lung function was unchanged, but there was a small increase in short-acting beta2-agonist use.
Predictors of efficacy to tiotropium
Airway obstruction and acute bronchodilator reversibility predicted a positive FEV1 response to tiotropium in adults whose asthma was not well controlled by low-dose ICS and who were not taking a LABA 18, 25 . In this study, neither gender, body mass index, asthma duration, atopic status, serum IgE, sputum eosinophils or fraction of exhaled nitric oxide were predictive 25 
Adverse effects of tiotropium
Data on adverse events pooled from seven phase II and III randomized controlled trials of 12 to 52 weeks' duration of once-daily tiotropium 5 μg and 2.5 μg (Respimat) versus placebo as addon to different background maintenance therapy was reported in 3474 adults with symptomatic asthma, of whom 2157 received tiotropium 28 . The proportion of participants with adverse events was similar between groups. Dry mouth was reported by 1% of the tiotropium 5 μg daily group, 0.4% of the tiotropium 2.5 μg daily group and 0.5% in the placebo group.
Cardiac adverse events occurred in 1.4% of patients and were similar between the study groups. Serious adverse events were comparable: 5% in the tiotropium 5 μg daily group, 2% in the tiotropium 2.5 μg daily group and 3.3% to 4.9% in the placebo groups. The UK Medicines within the past year 30 . Tiotropium should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction.
Umeclidinium
A phase II study of the LAMA umeclidinium in combination with the ICS fluticasone furoate demonstrated a dose-response improvement in trough FEV1 in adults with asthma compared fluticasone furoate alone 31 , whereas consistent bronchodilation was not found in adults with mild asthma who were not receiving ICS 32 . A 52-week phase III parallel group study is underway, comparing the efficacy and safety and of the fixed dose combination of the fluticasone furoate, umeclidinium and the LABA, vilanterol compared with the fixed dose combination of fluticasone furoate and vilanterol in subjects with inadequately controlled asthma despite ICS and LABA maintenance therapy (ClinicalTrials.gov Identifier: NCT02924688) 33 (Table 2 ).
Glycopyrronium
Several phase III 52-week parallel group trials are underway, comparing the fixed dose combination of the LAMA glycopyrronium with an ICS (extrafine beclometasone dipropionate or mometasone furoate) and a LABA (formoterol or indacaterol) in patients with uncontrolled asthma receiving medium or high dose ICS and LABA (ClinicalTrials.gov Identifiers:
NCT02676076; NCT02676089; NCT02571777) 33 (Table 2 ).
CRTH2 ANTAGONISTS
The chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) receptor, also known as the prostaglandin D2 receptor 2 (DP2), is expressed on Th2 cells, eosinophils, basophils, airway epithelial cells and type 2 innate lymphoid cells 29, 30 . Prostaglandin D2
activates the CRTH2 receptor to induce chemotaxis and cell activation. The oral CRTH2 receptor antagonists OC000459 and setipiprant both attenuated allergen-induced late asthmatic responses 34, 35 and reduced the associated sputum eosinophilia 34 . In patients with mild asthma not taking ICS, the administration of OC000459 for 4 to 12 weeks produced modest improvements in lung function and asthma control 36 , particularly in those with a blood eosinophilia 36, 37 . The oral CRTH2 receptor antagonist BI 671800 administered for 6 weeks to patients with mild asthma produced small improvement in FEV1 compared to placebo , but the changes were significantly less than those with fluticasone propionate, 440 μg daily 38 . Four weeks treatment with the oral CRTH2 antagonist AZD1981 failed to improve lung function in patients with asthma after ICS withdrawal or while receiving ICS 39 . An oral dual antagonist of human DP1 and CRTH2 receptors AMG 853, when added to ICS treatment, did not improve symptoms and lung function or reduce sputum eosinophils in patients with poorly controlled moderate to severe asthma 40 . In a phase II trial undertaken in 157 patients with mild to moderate allergic asthma, the oral CRTH2 antagonist fevipiprant (QAW039) did not improve lung function or asthma control, except in a subgroup with more severe airflow obstruction 41 .
A recent 12-week phase II exploratory trial investigated the efficacy of the fevipiprant (QAW039) 225 mg twice per day or placebo in 61 patients with persistent, moderate-to-severe asthma and an elevated sputum eosinophil count (≥2%) 42 . The main finding was that sputum eosinophil percentage (primary end-point) decreased from a geometric mean of 5·4% (95% CI 3·1 to 9·6) to 1·1% (0·7 to 1·9) in the fevipiprant group (a reduction of 4.5 times from baseline) and from 4·6% (2·5 to 8·7) to 3·9% (CI 2·3 to 6·7) in the placebo group (a reduction of 1.3 times from baseline group) (difference between groups 3·5 times, 95% CI 1·7 to 7·0; p=0·0014) 42 . (Table 2 ).
PHOSPHODIESTERASE INHIBITORS
Phosphodiesterase (PDE)4 inhibitors have anti-inflammatory effects on effector cells potentially relevant to the treatment of asthma [43] [44] [45] . In a Phase II allergen challenge study, the oral PDE4
inhibitor roflumilast attenuated the late phase response and the associated rise in sputum eosinophils and neutrophils numbers 46 . An overview of nine phase II and phase III placebocontrolled studies of roflumilast in asthma with a duration of 4 to 24 weeks found a trend for an improvement in FEV1, although changes reached statistical significant in only three studies 47 . In two phase III trials included in the review, the addition of roflumilast 500 μg daily to low doses of ICSs [beclomethasone dipropionate (BDP) or fluticasone propionate (FP)] found significant improvements in FEV1 (71 ml) compared to BDP 400 μg daily, but the changes were not significant compared to FP 250 μg daily. The improvement in FEV1 with roflumilast and BDP 400
were equivalent to BDP 800 μg daily 47 . A phase II cross-over study of roflumilast combined with montelukast in 64 patients with uncontrolled asthma despite treatment with medium dose ICS and LABA combination produced an improvement in FEV1 (100 ml) at 4 weeks compared to montelukast alone 48 . A pooled analysis of one open label and ten phase II and III studies of roflumilast at doses of 125, 250, and 500 μg daily for asthma involving 2851 participants reported that headache was the most frequent adverse effect with an incidence of 50 and 29.2 per 100 patients-years in the 500 μg roflumilast and placebo groups respectively 49 . Nausea and diarrhoea were also often associated with roflumilast use.
Inhaled formulation have been developed that may improve the therapeutic index of PDE4
inhibitors [50] [51] [52] . Inhaled PDE4 inhibitors GSK256066 and CHF6001 both inhibit allergen-induced late asthmatic responses 53, 54 . An inhaled dual PDE3 and PDE4 inhibitor RPL554 has bronchodilator effects and is well tolerated in patients with asthma 55 . A preliminary report of a Phase II trial of nebulized doses of RPL554 compared to salbutamol and placebo on lung function in patients with asthma found that RPL554 caused a dose dependent bronchodilation similar to salbutamol, but with fewer side effects 56 .
CXCR2 ANTAGONISTS
CXCR2 receptors are expressed on neutrophils as well as on airway goblet cells, fibroblasts and airway smooth and when activated by ligands such as the chemokines CXCL8 (IL-8) induces neutrophil chemotaxis, proteases production, airway goblet cell hyperplasia, collagen deposition and airway smooth muscle contraction and migration 57 . Neutrophilic airway inflammation is found in some patients with asthma although the role of neutrophils in the pathogenesis of asthma is uncertain 58 . A phase II study found that the 4-weeks treatment with CXCR2 antagonist SCH527123 reduced sputum neutrophil percentage by 36.3% in patients with severe asthma and sputum neutrophils > 40%. 59 
PROTEIN KINASE INHIBITORS
Inhibitors of protein kinases involved in cellular signalling of pro-inflammatory cytokines implicated in the pathogenesis of asthma may have a role in the treatment of severe asthma [61] [62] [63] [64] [65] . Several p38 mitogen-activated protein kinase (MAPK) inhibitors restore corticosteroid sensitivity in peripheral blood mononuclear cells (PBMCs) and alveolar macrophages from patients with severe asthma 63, 66 . A phase II trial is registered as investigating the efficacy and safety of the inhaled p38MAPK inhibitor AZD7624 in corticosteroid resistant asthma (ClinicalTrials.gov Identifier: NCT02753764) 33 . A specific c-kit tyrosine kinase inhibitor imatinib attenuates airway inflammation and remodelling in a murine model of asthma 67, 68 (Table 2 ).
SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
Non-steroidal selective glucocorticoid receptor agonists and modulators are in development with the aim of improving the therapeutic ratio of corticosteroids by dissociating transactivation, which is associated with the adverse effects of corticosteroids, from the beneficial effect through inhibition of pro-inflammatory gene transcription (transrepression) [70] [71] [72] . This concept has been challenged as it does not account for the observations that the production of anti-inflammatory proteins may have a more important role in resolution of inflammation than previously considered 73 . Only a small number of these molecules have been tested in asthma. An inhaled glucocorticoid receptor agonist GW870086 attenuated adenosine induced bronchoconstriction in asthma 74 , although chronic dosing did not improve lung function or reduces rescue medication use in patients with mild to moderate asthma 75 . A nonsteroidal glucocorticoid receptor agonist AZD5423 reduced the fall in FEV1 and sputum eosinophilia during the late asthmatic response induced by allergen challenge 76 . The efficacy and safety of a nonsteroidal glucocorticoid receptor agonist AZD7594 has undergone phase II clinical evaluation in patients with mild to moderate asthma (ClinicalTrials.gov Identifier:
NCT02479412) 33 , although to date, results of the study have not been published.
MACROLIDES
Macrolides possess pharmacological properties that are potentially relevant to the treatment of asthma, such as antibacterial and antiviral activity 77, 78 . Anti-inflammatory properties of macrolides include inhibition of nuclear factor-κB, reduction in neutrophil migration and/or function [79] [80] [81] [82] [83] and attenuation of tumor necrosis factor  and interleukin-17 immune responses 84 .
Macrolides also restore corticosteroid sensitivity through phosphoinositide 3-kinase (PI3K) pathway inhibition [85] [86] [87] . The macrolides most commonly used in clinical trials in asthma include azithromycin, clarithromycin, roxithromycin and troleandomycin 88 . Novel analogues of macrolides have been developed, such as solithromycin (CEM-101) that has enhanced anti-inflammatory properties compared to current macrolides, 83, 86 , the non-antibiotic azithromycin derivative CSY0073 that lacks anti-bacterial properties 89 and the oleandomycin derivative MAC5 that has enhanced ant-viral activity 90 Long-term treatment increases the risk of the development of microbial resistance 79 .
STATINS
The pleiotropic immunomodulatory properties of statins 93 and their ability to restore corticosteroid sensitivity 94, 95 suggest that statins may improve clinical outcomes in asthma 93, [96] [97] [98] [99] .
A small number of randomized controlled trials in adults with mild to moderate asthma found that short-term statin treatment did not improve lung function or symptom control in non-smokers with asthma 100 . In smokers with asthma, atorvastatin treatment resulted in a small improvement in asthma quality of life and symptoms that were associated with reductions in several sputum cytokines, chemokines and growth factors concentrations unresponsive to ICS treatment 101, 102 .
Several observation studies report that statin use in asthma is associated with a reduced risk of asthma-related emergency department visits, oral corticosteroid dispensing or hospital admissions 
